Aktuelle Studien
Hier eine Übersicht unserer aktuell laufenden Studien
| Name | Eudrat-Nummer | Status |
|---|---|---|
| ACCLAIM-Lp(a) - Lilly A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event | 2023-509190-23-00 | Probanden gesucht |
| REIMAGINE 2 - Novo Nordisk A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight in people with type 2 diabetes treated with metformin with or without an SGLT2 inhibitor | 2022-502678-18-00 | Rekrutierungsphase abgeschlossen |
| Diabetes (ATTAIN-2) - Lilly A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once- Daily Oral LY3502970 Compared with Placebo in Adult Participants with Obesity or Overweight and Type 2 | 2022-502837-24-00 | Rekrutierungsphase abgeschlossen |
| SURPASS-EARLY - Lilly A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared with Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes | 2022-501073-40-00 | Rekrutierungsphase abgeschlossen |
| HORIZON - Novartis Efficacy, safety, tolerability and quality of life of ongoing individually optimized lipid-lowering therapy with or without Inclisiran – a randomized, placebo-controlled, double-blind multicenter phase IV study in participants with hypercholesterolemia | 2021-003759-40 | Rekrutierungsphase abgeschlossen |
| SURPASS-CVOT - Lilly The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes | 2019-002735-28 | Rekrutierungsphase abgeschlossen |